[{"id":"91561dac-30a2-4a93-98b9-a8a30dc2db38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411133","created_at":"2022-06-09T13:55:21.916Z","updated_at":"2024-07-02T16:35:22.665Z","phase":"Phase 1","brief_title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","source_id_and_acronym":"NCT05411133","lead_sponsor":"Arbele Pty Ltd","biomarkers":" CDH17","pipe":" | ","alterations":" CDH1 expression","tags":["CDH17"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cabotamig (ARB202)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-01-23"}]